Physician profile
Suzanne E Chang
NPI 1780603852
$5,841.41
in general payments reported to CMS, 2019-2025
49 companies · $920 in 2025
The $920 reported for 2025 was more than what 84% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $591 · 2020: $413 · 2021: $741 · 2022: $1,183 · 2023: $1,130 · 2024: $865 · 2025: $920.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,914.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,914.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,211.92 | 2019-2025 | Vraylar, Ubrelvy |
| Glaxosmithkline, LLC. | $550.77 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals Lp | $426.51 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Lilly USA, LLC | $411.56 | 2019-2025 | Mounjaro, Jardiance, Emgality |
| Novo Nordisk INC | $314.28 | 2019-2023 | Ozempic, Rybelsus |
| Pfizer INC. | $223.30 | 2019-2025 | |
| Antares Pharma, INC. | $212.47 | 2022-2025 | Xyosted, Nocdurna, Tlando |
| Bayer Healthcare Pharmaceuticals INC. | $194.94 | 2022-2025 | |
| Amgen INC. | $193.09 | 2019-2025 | Otezla, Repatha, Otezla |
| Genzyme Corporation | $170.22 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $166.78 | 2019-2025 | Jardiance, Tradjenta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $134.09 | 2022-2025 | Xifaxan |
| Verity Pharmaceuticals INC. | $127.99 | 2024-2025 | Tlando |
| Corcept Therapeutics | $119.53 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $110.14 | 2023-2024 | Nuedexta, Rexulti |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Suzanne Chang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.